The best way to streamline target discovery and reduce late-stage failure is to prioritize the right target – and the best way to win the lottery is to know the winning number. 

A recent study from the Wellcome-Sanger Institute and Sanofi found a common denominator between successful candidates. Therapeutic targets with clear cell type specificity in disease-relevant tissues were more likely to succeed.

Let’s put this information to work supporting more confident, efficient discovery decisions. We’ll explore curated single-cell datasets with enriched pathway, regulatory network and cell level variation data and apply them towards target discovery.

Want to learn more? Check out the study.